<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Blockade of programmed <z:hpo ids='HP_0011420'>death</z:hpo> 1 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1), an inhibitory receptor expressed by T cells, can overcome immune resistance </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We enrolled patients with advanced <z:hpo ids='HP_0002861'>melanoma</z:hpo>, <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e>, castration-resistant <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, or renal-cell or <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> to receive anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 antibody at a dose of 0.1 to 10.0 mg per kilogram of body weight every 2 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>Response was assessed after each 8-week treatment cycle </plain></SENT>
<SENT sid="4" pm="."><plain>Patients received up to 12 cycles until disease progression or a complete response occurred </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: A total of 296 patients received treatment through February 24, 2012 </plain></SENT>
<SENT sid="6" pm="."><plain>Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three <z:hpo ids='HP_0011420'>deaths</z:hpo> from pulmonary toxicity </plain></SENT>
<SENT sid="7" pm="."><plain>No maximum tolerated dose was defined </plain></SENT>
<SENT sid="8" pm="."><plain>Adverse events consistent with immune-related causes were observed </plain></SENT>
<SENT sid="9" pm="."><plain>Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were observed in those with <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e>, <z:hpo ids='HP_0002861'>melanoma</z:hpo>, or <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal-cell cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Cumulative response rates (<z:hpo ids='HP_0000001'>all</z:hpo> doses) were 18% among patients with <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e> (14 of 76 patients), 28% among patients with <z:hpo ids='HP_0002861'>melanoma</z:hpo> (26 of 94 patients), and 27% among patients with <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal-cell cancer</z:e> (9 of 33 patients) </plain></SENT>
<SENT sid="11" pm="."><plain>Responses were durable; 20 of 31 responses lasted 1 year or more in patients with 1 year or more of follow-up </plain></SENT>
<SENT sid="12" pm="."><plain>To assess the role of intratumoral <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 ligand (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1) expression in the modulation of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1 pathway, immunohistochemical analysis was performed on pretreatment <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens obtained from 42 patients </plain></SENT>
<SENT sid="13" pm="."><plain>Of 17 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1-negative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, none had an objective response; 9 of 25 patients (36%) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had an objective response (P=0.006) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 antibody produced objective responses in approximately one in four to one in five patients with <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small-cell lung cancer</z:e>, <z:hpo ids='HP_0002861'>melanoma</z:hpo>, or <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal-cell cancer</z:e>; the adverse-event profile does not appear to preclude its use </plain></SENT>
<SENT sid="15" pm="."><plain>Preliminary data suggest a relationship between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-L1 expression on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and objective response </plain></SENT>
<SENT sid="16" pm="."><plain>(Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT00730639.) </plain></SENT>
</text></document>